EP4719415A2 - Composés radiomarqués de triméthoprime et leurs utilisations - Google Patents

Composés radiomarqués de triméthoprime et leurs utilisations

Info

Publication number
EP4719415A2
EP4719415A2 EP24816405.5A EP24816405A EP4719415A2 EP 4719415 A2 EP4719415 A2 EP 4719415A2 EP 24816405 A EP24816405 A EP 24816405A EP 4719415 A2 EP4719415 A2 EP 4719415A2
Authority
EP
European Patent Office
Prior art keywords
cells
cell
edhfr
compound
tmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24816405.5A
Other languages
German (de)
English (en)
Inventor
Mark A. Sellmyer
Nitika Sharma
Jean M. ETERSQUE
Swarbhanu SARKAR
Hwan Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP4719415A2 publication Critical patent/EP4719415A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule I, II ou III ou des sels pharmaceutiquement acceptables de ceux-ci, R1-R4, R11-R14, R31, R33 et R34 étant tels que définis dans la description. L'invention concerne également des compositions comprenant les composés, des procédés d'utilisation des composés pour administrer un rayonnement à des cellules ou des tissus exprimant la dihydrofolate réductase (DHFR), tuer une cellule ou un tissu comprenant la dihydrofolate réductase d'E. coli (eDHFR), ou traiter un cancer chez un sujet en ayant besoin.
EP24816405.5A 2023-05-30 2024-05-30 Composés radiomarqués de triméthoprime et leurs utilisations Pending EP4719415A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363505029P 2023-05-30 2023-05-30
PCT/US2024/031640 WO2024249610A2 (fr) 2023-05-30 2024-05-30 Composés radiomarqués de triméthoprime et leurs utilisations

Publications (1)

Publication Number Publication Date
EP4719415A2 true EP4719415A2 (fr) 2026-04-08

Family

ID=93658837

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24816405.5A Pending EP4719415A2 (fr) 2023-05-30 2024-05-30 Composés radiomarqués de triméthoprime et leurs utilisations

Country Status (2)

Country Link
EP (1) EP4719415A2 (fr)
WO (1) WO2024249610A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534418B2 (en) * 2004-12-10 2009-05-19 The Regents Of The University Of Michigan Imaging agents
ES2914099T3 (es) * 2014-08-25 2022-06-07 Salk Inst For Biological Studi Inhibidores novedosos de ULK1 y métodos de uso de los mismos
IL302457A (en) * 2020-10-30 2023-06-01 Blueprint Medicines Corp Pyrimidine compounds, preparations and their medical applications

Also Published As

Publication number Publication date
WO2024249610A2 (fr) 2024-12-05
WO2024249610A3 (fr) 2025-04-17

Similar Documents

Publication Publication Date Title
Liu et al. Exploring treatment options in cancer: tumor treatment strategies
Weist et al. PET of adoptively transferred chimeric antigen receptor T cells with 89Zr-oxine
JP7351533B2 (ja) 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
CN110730908B (zh) 表达前列腺特异性膜抗原（psma）或其修饰形式的工程化细胞及相关方法
EP3507304B1 (fr) Compositions et méthodes pour le traitement du cancer avec des duocars
EP3272364B1 (fr) Anticorps thérapeutiques chimériques
EP3845557B1 (fr) Procédé de traitement de cancer à l'aide de lymphocytes t génétiquement modifiés
Ponomarev et al. A human-derived reporter gene for noninvasive imaging in humans: mitochondrial thymidine kinase type 2
JP7501991B2 (ja) 抗体及び関連分子並びにその使用
US20220403051A1 (en) A DOTA binding chimeric antigen receptor for cellular therapy
KR102412805B1 (ko) 세포 면역 요법을 위한 조성물 및 방법
Wadhwa et al. CD46-Targeted theranostics for PET and 225Ac-radiopharmaceutical therapy of multiple myeloma
CA3247423A1 (fr) Cellules ayant un squelette de ciblage de tumeur solide et leur utilisation
Tomai et al. Challenges in the preclinical design and assessment of CAR-T cells
CN120641436A (zh) 基于内含肽的分选系统和模块化嵌合多肽
JP2022531229A (ja) 併用治療
WO2024249610A2 (fr) Composés radiomarqués de triméthoprime et leurs utilisations
US20200316231A1 (en) Compositions And Methods For Imaging Immune Cells
US20250170180A1 (en) Treatment of cancers with a regimen of targeted radionuclide therapy and dual car t cell therapy
Gosmann Non-invasive in vivo monitoring of human T cells via immunoPET to evaluate response patterns of cancer immunotherapies
Mirzaei et al. Challenges in the preclinical design and assessment of CAR-T cells
Hou et al. Next Generation of Solid Target Radionuclide Antibody Conjugates for Tumor Immuno‐Therapy
KR20260026491A (ko) 표적 방사성 핵종 치료 및 유전자 조작 면역 세포 치료의 용법에 의한 고형 종양의 치료
TW202417618A (zh) 具有實體腫瘤靶向主鏈之細胞及其用途
HK40051840B (zh) 工程化嵌合抗原受体(car)t细胞的人应用

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251223

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR